Sargramostim as a Vaccine Adjuvant

Time: 9:30 am
day: Day Two


  • GM-CSF induction of non-lymphoid tissue-resident dendritic cells (DCs) is
    imperative for CD8+ T cell responses, leading to a history of GM-CSF use as an
    adjuvant in numerous vaccines.
  • Studies have reported both increased immune responses and immune
    suppression, depending upon GM-CSF dosage and frequency.
  • Concurrent strategies to suppress immunoregulatory cells may enhance GMCSF-
    mediated DC induction as a strategy to boost adjuvanticity in emerging
    vaccine therapies.